This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

OncoMed To Present Data On Anti-Cancer Stem Cell Candidates At The American Association Of Cancer Research Meeting

Stocks in this article: OMED

REDWOOD CITY, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will provide an extensive update on its anti-cancer stem cell pipeline at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 in at the San Diego Convention Center in San Diego, CA.

"The nine presentations at the upcoming AACR meeting highlight the strength our research team's ongoing efforts to constantly advance our knowledge of cancer stem cell pathways, predictive biomarkers and anti-tumor activity for our growing pipeline of candidates," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed. "These data add to the increasing body of information for OncoMed's clinical-stage candidates and provide results from studies of OncoMed's most advanced preclinical candidates, a bispecific antibody that blocks DLL4 and VEGF signaling and an antibody that targets the RSPO-LGR cancer stem cell pathway." 

The list of abstracts and timing of the presentations by OncoMed scientists is provided below.

Oral Presentation
1. "Using PDX Models for Anticancer Drug Screening" will be presented by Timothy Hoey, PhD, Senior Vice President, Cancer Biology.
Date and time: Saturday, April 5, 2014, 10:45 am – 11:10 am PT
Location: Room 25A-C
Session: Methods Workshop, "Applications of Patient Derived Xenograft Models to Translational Cancer Research"
2. "NOTCH3 expression is predictive of efficacy in pancreas tumor models treated with OMP-59R5, a monoclonal antibody targeting the NOTCH2 and NOTCH3 receptors" (Abstract #910) will be presented by Belinda Cancilla, PhD, Director.
Date and time: Sunday, April 6, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 37: Predictive Biomarkers 1
3. "Dual targeting of DLL4 and VEGF signaling by a novel bispecific antibody inhibits tumor growth and reduces cancer stem cell frequency" (Abstract #207) will be presented by Wan-Ching Yen, PhD, Senior Scientist II.
Date and time: Sunday, April 6, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 8: Stem Cell Expansion and Anti-Cancer Stem Cell Targeting
4. "Inhibition of R-spondin (RSPO) signaling reduces the growth of multiple human tumors" (Abstract #1764) will be presented by Austin Gurney, PhD, Senior Vice President, Molecular and Cellular Biology. 
Date and time: Monday, April 7, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 32: New Targets and Agents 1
5. "The combination of gemcitabine/ nab-paclitaxel and anti-DLL4 (demcizumab) produces synergistic growth inhibition, delays tumor recurrence and reduces tumor initiating cells in pancreatic cancer" (Abstract #1898) will be presented by Dr. Hoey. 
Date and time: Monday, April 7, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 37: New Diagnostics, Therapeutic Targeting, and Response Assessments
6. "Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models" (Abstract #1907) will be presented by Pete Yeung, Associate Scientist.
Date and time: Monday, April 7, 2014, 1:00 pm – 5:00 pm PT 
Location: Hall A-E
Poster Section 1: Cancer Stem Cell Phenotype and Function 1
7. "Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) by mining gene expression data of human breast cancer xenografts" (Abstract #2830) will be presented by Chun Zhang, PhD, Sr. Scientist II. 
Date and time: Monday, April 7, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 37: Predictive Biomarkers 2 
8. "OMP-59R5 (Anti-Notch2/3) inhibits tumor growth and reduces cancer stem cell frequency in patient derived SCLC xenografts" (Abstract #3048) will be presented by Marcus Fischer, Associate Scientist.
Date and time: Tuesday, April 8, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 4: Cancer Stem Cell Phenotype and Function 2 
9. "Enhanced anti-tumor effect of WNT pathway antagonists in combination with taxanes" (Abstract #4547) will be presented by Dr. Yen.
Date and time: Tuesday, April 8, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 31: Cell Cycle Mechanisms of Anticancer Drug Action

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs